ACTON, Mass.–(BUSINESS WIRE)–“2015 World Medical Innovation Forum” cites “Early Diagnosis and Treatment of Alzheimer’s Disease” as the top field where breakthroughs will be made
Author: Business Wire
Dr Robert Lanza, Chief Scientific Officer of Ocata Therapeutics to be a Featured Speaker at The Common Good Forum
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that Robert Lanza, M.D., will be a featured speaker at The Common Good Forum “Venture Economics, Public Policy & Investment: Our Nation’s Future” on May 14, 2015, at the Waldorf Astoria in New York City. “Dr. Lanza’s pioneering research is providing hope for millions of people who may one day benefit from breakthrough c
BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT:BTX) today reported financial results for the first quarter ended March 31, 2015 and provided a corporate update. “BioTime continues to advance its strategic product development programs. We are currently enrolling patients in a pivotal trial of Renevia™ for the treatment of HIV-associated lipoatrophy,” said Dr. Michael D. West, BioTime’s Chief Executive Officer. “At this year’s annual meeting of the American Association for Cancer Resea
Presbia Cooperatief U.A. to Participate in Jefferies Healthcare Conference
DUBLIN–(BUSINESS WIRE)–PRESBIA TO PARTICIPATE IN JEFFERIES HEALTHCARE CONFERENCE
NovaBay Pharmaceuticals to Feature Key Opinion Leaders in Ophthalmology and Optometry at Analyst and Investor Day Event on May 19
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals Features Key Opinion Leaders in Ophthalmology and Optometry in Analyst and Investor Day Event on May 19
Isarna Presents Positive Preclinical Results Supporting Development of ISTH0036 for the Treatment of Glaucoma
MUNICH–(BUSINESS WIRE)–Our preclinical data support the compound’s potential to protect glaucoma patients’ vision and we see other high medical need diseases that could potentially benefit from TGF-β-targeted treatment.
Research and Markets: Seeing into the Future: New Opportunities on the Horizon for Smart Eyewear
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/d8s63g/seeing_into_the) has announced the addition of the “Seeing into the Future: New Opportunities on the Horizon for Smart Eyewear” report to their offering. T…
pSivida Corp. Reports Third Quarter FY 2015 Results
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida reports third quarter FY 2015 results; Clear FDA Regulatory Path for Medidur for Posterior Uveitis; NDA filing planned in first half of 2017
Aerie Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Business and Strategic Update
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported financial results for the first quarter ended March 31, 2015. The Company will host a live conference call and webcast at 5:00 p.m. Eastern
Eleven Biotherapeutics Presents Clinical Data on EBI-005 for the Treatment of Dry Eye Disease and Allergic Conjunctivitis at ARVO 2015 Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Clinically Relevant, Statistically Significant Improvements of Symptoms in the Late Phase of Allergic Conjunctivitis with EBI-005 Supports Advancing to a Phase 3 Natural Environment Study
InSite Vision to Report First Quarter 2015 Results on May 14, 2015
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the first quarter ended March 31, 2015 on Thursday, May 14, 2015.
Aerie Pharmaceuticals Elects Richard Croarkin to the Company’s Board of Directors
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Richard Croarkin has been elected to the Company’s Board of Directors, effective May 7, 2015. Mr. Croarkin brings extensive financial experience acro
R-Tech Ueno: Termination of License Agreements for Unoprostone
TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ: 4573) R-Tech Ueno, Ltd. (RTU) today announced it has signed a termination agreement with Sucampo AG (SAG), one of the subsidiaries of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (Sucampo), which terminates,…
Ocular Therapeutix™ to Report First Quarter 2015 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fi…
NovaBay Pharmaceuticals’ Avenova Brings Significant Improvement to Patients With Blepharitis, New Study Finds
SAN DIEGO & EMERYVILLE, Calif.–(BUSINESS WIRE)–Family Eye Care Optometry and NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announced that Guru Sharma O.D. Ph.D., Optometrist at Family Eye Care Optometry and Assistant Professor at Western University of the Health Sciences’ College of Optometry, presented new research documenting the successful use of Avenova™ on patients with blepharitis during the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Dr. Sharma’s
New Laboratory Study Shows that NovaBay Pharmaceuticals’ Avenova Completely Inactivates the Bacterial Enzyme that Contributes to Blepharitis and Meibomian Gland Dysfunction
PHOENIX & EMERYVILLE, Calif.–(BUSINESS WIRE)–Phoenix Eye Care and NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announced that Dr. Arthur B. Epstein, Director of Clinical Research and head of the Dry Eye – Ocular Surface Disease Center at Phoenix Eye Care, discussed the benefits of NovaBay’s Avenova™ lid & lash cleanser at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). The poster presentation was held today, May 6, from 11:00 a.m.–12:45 p.m. Centra
SCRA Technology Ventures Company Signs Research Agreement
SUMMERVILLE, S.C.–(BUSINESS WIRE)–SCRA Technology Ventures company, FirstString Research, announces CRADA to advance therapeutic for diabetic keratopathy and persistent corneal defects.
Mati Therapeutics Expands Patent Portfolio
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced today that it has been granted U.S. Patent No. 9,011,361 entitled “Lacrimal Implant Detection” and European Union Patent No. EP2614844 entitled “Drug Cores for Sustained Release of Therapeutic Agents.” These patents provide coverage for important elements of Mati’s novel punctal plug delivery system (“PPDS”) for treatment of ocular indications including certain features for detecting the implants in the puncta and in the
Research and Markets: Global and Chinese Soft Hydrophilic Contact Lens Industry, 2010-2020 Market Research Report
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/c33pgm/global_and) has announced the addition of the “Global and Chinese Soft Hydrophilic Contact Lens Industry, 2010-2020 Market Research Report” report to their…
Ophthotech Corporation to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015.